Legend Star helps entrepreneurs create great businesses through investments, CEO training sessions and an entrepreneurs alliance.   Since 2008, Legend Star has incubated and invested in nearly 600 companies and is deeply integrated in the Chinese entrepreneurial ecosystem.   Legend Star is the independent early-stage investment arm of Legend Holdings. Legend Holdings is the parent company of Lenovo, Raycom Real Estate, Joyvio Agribusiness and a large range of fast-growing Chinese companies.

Legend Star

LYFE Capital is a pure play healthcare focused investment firm.  We believe that “Healthcare has no boundaries”, and that every new choice we made has the potential to advance healthcare and solve the unmet needs for everyone. LYFE Capital operates 5 global offices including our US headquarters in Menlo Park, California, our Asia headquarters in Singapore, as well as locations in Seoul, Tokyo and Shanghai. We leverage our expertise and global resources to invest in and create value for healthcare companies across the globe.  LYFE Capital’s investments span medical devices, therapeutics, diagnostics, and emerging sectors across North America and Asia.

LYFE Capital

HongShan is a VC firm focused on seed-stage, mid-stage, late-stage, and growth investments in the fintech sector. HongShan has offices in Hong Kong, Beijing, Shanghai, Guangzhou, Hangzhou, Suzhou, and Shenzhen. Over the past nine years, Sequoia Capital China has an impressive and diverse portfolio comprising about 300 dynamic companies that deliver high returns on investment using differentiated technologies and innovative business models, including Alibaba, VIPshop.com, Sina.com, Didi, JD.com, Ourpalm, Qihoo 360, Jumei, Momo, SINNET, Dianping.com, Meituan, Meilishuo, Toutiao, AutoNavi, Ganji.com, DJI, VanceInfo, Noah Private Wealth Management, Wanda Cinemas, Alibaba Pictures, Plateno Hotels Group, Deppon Logistics, ZTO Express, Beta Pharma, Snibe Diagnostic, BGI, WEGO, and Yuwell Medical.

HongShan

CMB International Capital Corporation is an investment banking firm that offers comprehensive professional services and financial advisory services. It provides mergers and acquisitions, initial public offering, equity underwriting, company restructuring, project financing, and business consulting services.  CMB International Capital Corporation provides corporate finance, asset management, wealth management and securities brokerage services. Additionally, it offers debt financing and transaction advisory services, placement of shares and refinancing for listed companies.  CMB International Capital Corporation’s clientele include institutional, corporate and individual customers both domestic and overseas. It began operation in 1987, with its headquarters in Central in Hong Kong as a subsidiary of China Merchants Bank.

CMB International Capital Corporation

Northern Light Venture Capital was founded by general partners Feng Deng and Yan Ke on January 1, 2005.  Currently it is managed by five Managing Directors.  It manages approximately US$ 1.5 billion in committed capital with 4 US$ funds and 4 RMB funds, investing in more than 180 portfolio companies and seed investments to date.  NLVC is led by a partnership of accomplished local Chinese and ''''returnee'''' executives (''''returnees'''' are those who grew up in mainland China but studied or worked abroad before returning) with significant investing and entrepreneurial accomplishments. Its management team includes Feng Deng, former member of the board at NetScreen (a pioneering IT security firm), Yan Ke, vice President of Netscreen, and Lei Yang, chairman of Vantage Point Venture Partners.  NLVC is a China concept venture capital firm focused on early and growth stage opportunities which targets businesses that leverage China’s industrial, economic, or human resources to build exceptional, lasting enterprises in the global economy.  NLVC focuses on early and growth stage opportunities in information technology, new media, TMT, clean technologies, consumer service and healthcare. Portfolio companies include Meituan.com, Kaixin001.com, Gogo.com, redbaby.com, MasaMaso.com, and Velo City.

Northern Light Venture Capital

GIC is a global investment firm established in 1981 to manage Singapore's foreign reserves. A disciplined long-term value investor, GIC is uniquely positioned for investments across a wide range of asset classes, including equities, fixed income, private equity, real estate, and infrastructure. GIC invests through funds and directly in companies, partnering with its fund managers and management teams to help world-class businesses achieve their objectives. In tech investing, GIC seeks to be a lifetime partner to the companies it invests in. GIC has investments in over 40 countries around the world. Headquartered in Singapore, GIC employs over 1,700 people across 10 offices in key financial cities worldwide.

Lilly Asian Ventures makes venture capital investments in Asia for Eli Lilly and Company, a global innovation-driven pharmaceutical company. Lilly Asian Ventures invests in promising life science companies with strong management teams and innovative technology and/or business models. Their initial focus will be primarily on opportunities in China, although they will consider investment opportunities elsewhere in east and south Asia.

Lilly Asia Ventures

Taihe Capital is an equity investment management company specializing in science and technology innovation.

Taihe Capital

Burning Rock Biotech

Burning Rock focuses on providing individualized cancer treatment guidance for the patients. Using medical and bio informatics plus Next-Generation Sequencing (NGS) as the core technologies, the company is committed to offering one-stop solution for clinical and R&D services concerning the genetic testing of individualized cancer treatment. Established in March 2014, Burning Rock is headquartered in Beijing. Its first medical laboratory, ''Guangzhou Burning Rock Medical Examination Institute Co., Ltd.'' is situated on Guangzhou International Bio Island which is blessed with a picturesque environment and rich in scientific research deposits. Later it established a R&D center in Shanghai. It occupies over 10,000 ㎡ in total. Burning Rock is committed to guiding the individualistic treatment of tumor patients, centered around NGS and biomedical informatics, with conventional tumor molecular pathology detection as the cornerstone, trying to build one-stop solutions for individualistic treatment clinical detection service and scientific research of tumor.

Burning Rock Biotech is a precision oncology company that focuses on applying next-generation sequencing (NGS) technology. It offers NGS-based therapy selection testing for late-stage cancer patients, cancer early detection tests moving into the clinical validation stage, and pharmaceutical R&amp;D services. The company’s NGS technology analyzes genetic mutations in tumors to provide personalized cancer treatment recommendations. Its early detection tests use methylation biomarkers and ML algorithms to detect multiple cancer types from blood samples.

Burning Rock's minimal residual disease (MRD) product supports advancement in early-stage non-small cell lung cancer treatment, with results published in the Cancer Cell

Bayer and Burning Rock collaborate to increase patient access to precision cancer medicines

Burning Rock Received Breakthrough Device Designation from China’s NMPA for its Multi

Updated: Cancer treatment firm Burning Rock kicks off $209m US IPO

Burning Rock Received Breakthrough Device Designation from China’s NMPA for its Multi-Cancer Early Detection Test

Leveraging personal data for custom-fit diagnosis and treatment

Precision Medicine

Burning Rock Biotech, Dizal announce NMPA approval for sunvozertinib CDx

Bayer

To develop next-generation sequencing (NGS)-based companion diagnostic assays (CDx) to enable treatment choices for cancer patients in China.

Companies that develop an in-vitro medical device or imaging tools and tests that identify genetic mutations for both diagnostic (nature of the disease) and prognostic (likely course of the disease) purposes, allowing providers to match a patient to a specific drug or therapy.

To develop a co-branded solution for businesses to manage finances more efficiently using the Rho Corporate Card.

Making banking work, without the paperwork

Neobanks

Platforms offering digital checking and savings accounts that target businesses and freelancers

Burning Rock biotech Limited is a biotechnology company that specializes in the application of next-generation sequencing (NGS) technology in precision oncology. The company's primary focus is on developing and providing NGS-based therapy selection testing for late-stage cancer patients, global pharmaceutical services for biomarker detection and companion diagnostics development, and early cancer detection solutions. Burning Rock's flagship product, OverC Multi-Cancer Detection Blood Test (MCDBT), is designed for the early detection of multiple cancer types in adults aged 50-75 years old who are at average risk for cancer. As of March 2023, the OverC MCDBT demonstrated a sensitivity of 69.1% and a specificity of 98.9% in a case-control study. The company's technology, ELSA-seq, utilizes cell-free DNA for cancer detection and origin prediction. Burning Rock also offers CanCatch, a personalized Minimal Residual Disease (MRD) product, which has shown superior performance in head-to-head comparisons with other MRD assays for non-small cell lung cancer patients.

Burning Rock Biotech is a precision oncology company that focuses on applying next-generation sequencing (NGS) technology. It offers NGS-based therapy selection testing for late-stage cancer patients, cancer early detection tests moving into the clinical validation stage, and pharmaceutical R&amp;D services. The company’s NGS technology analyzes genetic mutations in tumors to provide personalized cancer treatment recommendations. Its early detection tests use methylation biomarkers and ML algorithms to detect multiple cancer types from blood samples.In&nbsp;<a href="https://ir.brbiotech.com/news-releases/news-release-details/burning-rock-secures-second-ngs-kit-approval-nmpa">March 2022</a>, its Human Nine-Gene Mutation Joint Detection Kit, LungCure CDx, received approval as a class III medical device from China's National Medical Products Administration (NMPA) as the company's second NMPA-approved product. In&nbsp;<a href="https://www.globenewswire.com/en/news-release/2023/09/08/2739852/0/en/Burning-Rock-s-minimal-residual-disease-MRD-product-supports-advancement-in-early-stage-non-small-cell-lung-cancer-treatment-with-results-published-in-the-Cancer-Cell.html">September 2023</a>, Burning Rock commercially launched its personalized minimal residual disease (MRD) assay, brProphet, targeting early-stage cancer patients. Additionally, the company obtained breakthrough device designation from the US FDA and China NMPA for its OverC multi-cancer early detection blood test.Burning Rock reported revenue growth in 2022, driven by strong performance in its in-hospital channel and pharma services business. The company's in-hospital testing volume grew by 23% YoY, while its pharma business saw a 212% increase in revenue due to the backlog execution of contracts, primarily due to delays related to the COVID-19 pandemic.&nbsp;

<div>
 
 Praxis Precision Medicines is a clinical-stage biopharmaceutical company that develops precision medicine for central nervous system disorders based on neuronal imbalance caused by genetic mutations.
 
 
 The company has four clinical-stage product candidates in its pipeline for treating disorders such as depression, epilepsy, movement disorders, and pain syndromes. The company&rsquo;s drug candidates include 1) PRAX-944, which is an inhibitor for essential tremor disorder linked to Parkinson&rsquo;s disease and is set to begin Phase 3 in mid-2023, 2) PRAX-222 in Phase 2 of clinical trials targets the SCN2A gene most commonly associated with early-onset epilepsy, 3) PRAX-562 was designed to block persistent sodium for patients suffering from rare diseases such as headache disorders and severe seizures and completed Phase 1 of clinical trials, and 4) PRAX-628 in Phase 2 clinical trials for treating focal epilepsy that originates in one side or area of the brain and affects one side of the body. Additionally, the firm has six pre-clinical drug candidates.
 
 
 Funding and financials
 
 
 The company went public in October 2020, trading on the Nasdaq Global Select Market under the ticker symbol &ldquo;PRAX&rdquo;. 
 <a href="https://sp-edge.com/updates/19453">
 In June 2023 
 </a>
 , the company announced an underwritten public offering of its common shares and pre-funded warrants, to raise approximately USD 59.1 million. The capital raised was used to support the company&rsquo;s ongoing operations and strategic initiatives, furthering the development of its pipeline and potential future endeavors.
 
 
 For the year 
 <a href="https://sp-edge.com/updates/16211">
 2022
 </a>
 , net losses increased by 28% YoY to USD 214 million arising from a significant increase in R&amp;D expense (up by 29% YoY). For the six months ended June 2023, the company is yet to generate revenue from drugs, however received collaboration revenue of USD 1.5 million. Further, it reported a decline in net loss by 43.0% YoY to USD 34.3 million. Its cash and cash equivalent as of June 2023 was at USD 124.3 million, compared to USD 61.6 million in December 2022, which the company believes will be adequate to fund operations till Q1 2025. 
 
</div>

Praxis Precision Medicines

<div>
 
 Mirati Therapeutics is a commercial-stage biotechnology company developing oncology-targeted therapies to address KRAS mutations present in 25% of tumors, including lung, colorectal and pancreatic cancers. Mirati&rsquo;s lead product KRAZATI (adagrasib/ MRTX849) is an oral&nbsp; KRASG12C inhibitor approved in 2022 for certain non-small cell lung cancers.The company also has sitravatinib, a multi-kinase inhibitor, in Phase 3 trials for non-small cell lung cancer in combination with a Bristol-Myers Squibb checkpoint inhibitor.
 
 
 
 
 Additionally, Mirati is advancing multiple early-stage programs including KRAS G12D inhibitor MRTX1133 for pancreatic and colorectal cancers, which entered Phase 1 in 2023, as well as a synthetic lethal inhibitor MRTX1719. In December 2022, the company submitted an IND application for MRTX1133, a potent and selective KRAS G12D inhibitor, which was cleared by the FDA in January 2023. 
 
 
 Key partnerships and customers
 
 
 
 
 Mirati has multiple partnerships with leading biopharma companies to advance its pipeline, including discovery collaborations with Pfizer and clinical collaborations with Novartis, Boehringer Ingelheim, and 
 <a href="https://sp-edge.com/updates/14345">
 Incyte
 </a>
 . The company also has licensing agreements with BeiGene for sitravatinib and Zai Lab for MRTX849 in certain Asian markets.
 
 
 
 
 
 Funding and Financials
 
 
 
 
 The company went public in June 2013 to trade on Nasdaq under the ticker symbol &ldquo;MRTX&rdquo;. In August 2023, the company closed an 
 <a href="https://sp-edge.com/updates/20988">
 underwritten public offering
 </a>
 at USD 345 million. The new funds were used towards drug development and leadership expansion.&nbsp;
 
 
 
 
 <a href="https://sp-edge.com/updates/16725">
 For the year 2022 
 </a>
 , the firm's net losses increased to USD 740.9 million from USD 581.8 million. Net product revenue for the full year amounted to USD 0.7 million arising from the sale of KRAZATI, which received FDA approval for its commercial launch in December 2022. 
 
</div>

Mirati Therapeutics

<div>
 
 Tvardi Therapeutics is a clinical-stage biotechnology company developing precision medicine for different cancers, chronic inflammatory diseases, and fibrotic diseases. The company&rsquo;s pipeline focuses on the development of small-molecule inhibitors of STAT3, a regulatory protein that allows cancer cells to evade the immune system and survive.
 
 
 The company&rsquo;s orally administered monotherapy and lead product, TTI-101, is in Phase 1 clinical trials for patients with advanced solid tumors who have failed all other lines of therapy. Additionally, the drug is in preclinical trials for treating fibrosis and inflammation. The company is also developing TTI-102, a next-generation STAT3 inhibitor that is structurally similar but chemically different from TTI-101.&nbsp;
 
 
 Founded in 2017, the Texas-based company closed a Series B funding round in June 2021, which brought total funding to USD 81 million and the proceeds will be used to advance Tvardi&rsquo;s drug candidates through its clinical data readouts in mid-stage trials for cancer and fibrosis.
 
</div>

Tvardi Therapeutics

<div>
 
 Tango Therapeutics is a clinical-stage biotech company developing precision oncology therapies targeting synthetic lethality in cancer which leads to cell death. Its discovery platform identifies novel targets to develop drugs focused on: 1) countering tumor suppressor gene loss to help the immune system recognize and kill cancer cells, and 2) reversing cancer cell evasion of the immune system.
 
 
 
 
 Tango has five pipeline programs, including lead candidate TNG908, an inhibitor for multiple cancer indicators. The FDA approved TNG908's IND in January 2022 and granted it Orphan Drug Designation. TNG908 is in Phase I/II trials, with preliminary efficacy data expected in H1 2023. Tango also plans to file INDs for TNG260 (STK11 mutant cancers) and TNG348 (BRCA1/2-mutant cancers). In 
 <a href="https://www.globenewswire.com/news-release/2023/01/25/2595034/0/en/Tango-Therapeutics-Announces-FDA-Clearance-of-Investigational-New-Drug-Application-for-TNG462-Provides-Additional-Business-Updates.html">
 January 2023
 </a>
 , the FDA cleared the IND for TNG462, a next-gen PRMT5 inhibitor for cancers with MTAP deletion.
 
 
 
 
 Key partnerships and customers
 
 
 
 
 
 Outside its pipeline, the company also entered into a collaborative partnership with big pharma Gilead Sciences Inc., in October 2018 which was later expanded for two years in August 2020 to identify new immune evasion targets.
 
 
 
 
 Funding and financials&nbsp;
 
 
 
 
 
 Tango went public in August 2021 via a SPAC deal, trading on Nasdaq under the ticker symbol &ldquo;TNGX&rdquo;, and the company received gross proceeds of USD 353 million. In August 2023, the company raised USD 80 million via a 
 <a href="https://sp-edge.com/updates/20955">
 private placement
 </a>
 , which was led by Nextech. The new funds were used toward expanding its TNG908 and TNG462 PRMT5 programs to various other indications.
 
 
 
 
 Tango has not yet generated any drug sales and does not expect to do so for several years. However, for the full-year the company reported collaboration revenue of USD 24.9 million (down 4.42% YoY) and a net loss of USD 108.2 million (up 85.9% YoY).
 
 
 
</div>

Tango Therapeutics

<div>
 
 IDEAYA Biosciences is a clinical-stage biotech developing precision cancer therapies based on synthetic lethality - when specific gene mutations pair to cause cell death. The company also studies combining synthetic lethality with immunotherapies and DNA damage to enhance treatment efficacy. While current drugs target limited mutations like BRCA1/2, IDEAYA aims to treat broader genetic subpopulations.&nbsp;
 
 
 
 
 Its pipeline includes synthetic lethality-driven precision medicines across four potential first-in-class clinical-stage product candidates. Of these, the company owns/controls commercial rights of the three most-advanced of these product candidates: darovasertib, IDE397, and IDE161. As of May 2024, the company was also advancing Werner Helicase program for which a development candidate has been selected in collaboration with GlaxoSmithKline, and, subject to investigational new drug-, or IND-, enabling studies, are targeting an IND in 2024. In addition. the company also works on multiple earlier-stage preclinical programs. 
 
 
 By targeting specific genetic drivers, IDEAYA advances precision oncology using synthetic lethality approaches. The company is focused on developing novel targeted therapies for patient populations with high unmet need and limited treatment options.&nbsp;&nbsp;
 
 
 In December 2023, IDEAYA Biosciences teamed up with Gilead Sciences to test the combination of IDE397 and Trodelvy in a Phase I clinical trial for MTAP-deletion bladder cancer.
 
 
 
 
 Key partnerships and customers
 
 
 
 
 The company collaborates with pharmaceutical partners to advance its pipeline, including a strategic partnership with GSK in June 2020. The collaboration with GSK covers co-development and commercialization of two synthetic lethality programs. IDEAYA received USD 100 million upfront and USD 20 million in a direct private placement through the GSK deal. In June 2022, IDEAYA announced it would co-develop its Pol Theta candidate with GSK, with a Phase 1 trial starting in the first half of 2023.&nbsp;
 
 
 
 
 IDEAYA also holds an exclusive license from Novartis for LXS196 (IDE196), a PKC inhibitor for metastatic uveal melanoma. Additionally, the company is exploring IDE196 combinations with Pfizer and its potential in other rare skin diseases. In July 2022, IDEAYA signed an agreement with Amgen to evaluate IDE397 with Amgen's AMG 193 in solid tumors. Strategic pharma partnerships help advance and expand IDEAYA's pipeline of synthetic lethality precision oncology programs.
 
 
 
 
 Funding and financials
 
 
 
 
 
 The company was listed on the Nasdaq Global Select Market under the ticker symbol &ldquo;IDYA&rdquo; in May 2019, raising USD 50 million via an initial public offering. In September 2022, the company raised USD 92 million.&nbsp;
 
 
 
 
 For 2022, the company reported a net loss of USD 58.7 million (up 17.9% YoY) while collaboration revenue was USD 50.9 million (up 82.3% YoY). 
 
 
 On October 24, 2023, IDEAYA Biosciences priced an underwritten public offering of 5 million shares of common stock and pre-funded warrants to purchase 319,150 shares of common stock. The common stock offered was priced at USD 23.50 per share, while the exercise price of a pre-funded warrant was USD 0.0001. The offering was expected to bring in approximately USD 125 million in gross proceeds.
 
 
 
</div>

IDEAYA Biosciences

Companies providing genetic tests to identify individuals with high risk or at-risk of having hereditary disease, aid physicians with a diagnosis, and support clinical decision making.

Secure cloud-based platforms and data sharing networks that collect, index, store, and analyze large amounts of health data and patient population data sets from sources including genomic, clinical, wearables, imaging, and population data.

Biopharma and biotechnology companies that develop precision medicine drugs based on novel disease biomarkers present in multi-omic patient population data and genetic insights.

Companies that study intergenomic variations in genes associated with drug response and metabolism to match patients with the appropriate drug and dosage.

Software analytics platforms that integrate multiple omics datasets (genomics, transcriptomics, proteomics, and metabolomics) to gain insights and support target discovery, drug development, clinical trials, and diagnostics.

Some companies leverage AI/ML to develop tailored medication

Considers individual variability in genes, environment, and lifestyle for each person

Genomics is used across all the segments of precision medicine from diagnostic solutions to treatments

AI/ML analyzes genomic data to find drug targets, predict disease progression, and treatment response

PROMINENT_CATEGORY

<div>
 Burning Rock Biotech is collaborating with Bayer to create next-generation sequencing (NGS)-based companion diagnostic assays (CDx) to guide treatment options for cancer patients in China.
 This partnership is strategized to advance CDx products in China, aiming at Bayer's escalating selection of precision cancer treatments. According to Burning Rock, by pooling resources and knowledge in cancer diagnosis and treatment, the cooperation hopes to establish a benchmark for precision oncology in China.
 Burning Rock is a biotech company that specializes in employing NGS technology in precision oncology. Its services include NGS-based therapy selection testing for late-stage cancer patients, global pharmaceutical services for biomarker detection, CDx solutions development, and early cancer detection.
</div>

Burning Rock Biotech

About EDGE

Contact Us

Resources

Area of Focus

Technology Research Made Effortless